- Home
- CCCC vs AACB Comparison
CCCC vs AACB Comparison
Compare CCCC & AACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCCC
- AACB
- Stock Information
- Founded
- CCCC 2015
- AACB 2024
- Country
- CCCC United States
- AACB United States
- Employees
- CCCC N/A
- AACB N/A
- Industry
- CCCC Biotechnology: Pharmaceutical Preparations
- AACB
- Sector
- CCCC Health Care
- AACB
- Exchange
- CCCC Nasdaq
- AACB Nasdaq
- Market Cap
- CCCC 242.3M
- AACB 283.7M
- IPO Year
- CCCC 2020
- AACB 2025
- Fundamental
- Price
- CCCC $2.44
- AACB $10.27
- Analyst Decision
- CCCC Strong Buy
- AACB
- Analyst Count
- CCCC 4
- AACB 0
- Target Price
- CCCC $8.50
- AACB N/A
- AVG Volume (30 Days)
- CCCC 1.5M
- AACB 9.5K
- Earning Date
- CCCC 11-06-2025
- AACB 01-01-0001
- Dividend Yield
- CCCC N/A
- AACB N/A
- EPS Growth
- CCCC N/A
- AACB N/A
- EPS
- CCCC N/A
- AACB N/A
- Revenue
- CCCC $30,108,000.00
- AACB N/A
- Revenue This Year
- CCCC N/A
- AACB N/A
- Revenue Next Year
- CCCC N/A
- AACB N/A
- P/E Ratio
- CCCC N/A
- AACB N/A
- Revenue Growth
- CCCC N/A
- AACB N/A
- 52 Week Low
- CCCC $1.09
- AACB $9.85
- 52 Week High
- CCCC $5.10
- AACB $10.29
- Technical
- Relative Strength Index (RSI)
- CCCC 49.92
- AACB N/A
- Support Level
- CCCC $2.39
- AACB N/A
- Resistance Level
- CCCC $2.63
- AACB N/A
- Average True Range (ATR)
- CCCC 0.16
- AACB 0.00
- MACD
- CCCC -0.00
- AACB 0.00
- Stochastic Oscillator
- CCCC 57.63
- AACB 0.00
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
About AACB Artius II Acquisition Inc. Class A Ordinary Shares
Artius II Acquisition Inc is a blank check company.